SCHEMBL9894641

SCHEMBL9894641

CC(=O)c1c(-c2ccc(F)cc2)nnn1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.41
GABRA5 P31644 2/20 0.41
PTGER4 P35408 3/20 0.38
LMNA P02545 1/20 0.38
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
MAPK14 Q16539 3/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPK1 P28482 1/20 0.36
TP53 P04637 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
PKM P14618 1/20 0.36
BLM P54132 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9894869 0.83 PTPN1 (0.45) GABRA5PTGER4LMNAALDH1A1HPGD
SCHEMBL9895018 0.75 MAPT (0.39) ALDH1A1HPGDKDM4ETP53MAPT
SCHEMBL25045153 0.74 NPC1 (0.45) PTGS2GABRA5ALDH1A1MAPK14MAPK13
SCHEMBL27915201 0.74 GABRA5 (0.43) GABRA5ALDH1A1HPGDMAPK14KDM4E
SCHEMBL2687825 0.72 CSNK1D (0.43) GABRA5ALDH1A1MAPK14MAPK13MAPK12
SCHEMBL2683463 0.72 GABRA5 (0.46) PTGS2GABRA5ALDH1A1MAPK14POLB
SCHEMBL16708689 0.71 POLB (0.45) PTGER4LMNAALDH1A1HPGDKDM4E
SCHEMBL12989454 0.71 NPC1 (0.41) KDM4ETP53POLBMAPTSMN1; SMN2
SCHEMBL14711183 0.71 LPAR1 (0.48) ALDH1A1HPGDPOLBMAPTPKM
SCHEMBL19715541 0.71 RAB9A (0.47) LMNAALDH1A1HPGDKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 PTGS2 2498/4885GABRA5 1/4885PTGER4 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.